Business
Here’s why the Imugene (ASX:IMU) share price is rising 9% today

The Imugene Limited (ASX: IMU) share price is on the rise today. This comes after the company received a successful outcome from the Cohort Review Committee (CRC) regarding its PD1-Vaxx immunotherapy.
PD1-Vaxx is a B-cell immunotherapy designed to treat tumours by producing polyclonal antibodies that block PD-1 signalling, causing an anti-cancer effect.
During mid-afternoon trade, the Imugene shares are up 9.5% to 12 cents.
First checkpoint passed
The Imugene share price is rising deeper into positive territory following the release.
According to Imugene, the CRC cleared the pathway for phase I clinical trials to be proceed with a higher dose of PD1-Vaxx.
Following patient data review, CRC unanimously decided that the immunotherapy…
-
Noosa News13 hours ago
Jessica Alba spotted filming spy thriller on the Gold Coast as cameras roll under iconic bridge
-
Noosa News10 hours ago
David’s neighbour died alone. He now knows what comes next
-
Noosa News19 hours ago
Good Charlotte are Touring Australia and New Zealand in 2026
-
Noosa News23 hours ago
A Marvel Heroes Guide to Sydney